Armstrong Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Armstrong Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74K	Hold	6	–	–	﹤0.01%	821
2026 Q1	$4.64K	Hold	6	–	–	﹤0.01%	790
2025 Q4	$4.63K	Hold	6	–	–	﹤0.01%	778
2025 Q3	$3.37K	Hold	6	–	–	﹤0.01%	807
2025 Q2	$3.15K	Sell	6 -20	-77%	-$11.2K	﹤0.01%	810
2025 Q1	$18.5K	Hold	26	–	–	﹤0.01%	528
2024 Q4	$18.5K	Buy	26 +6	+30%	+$5.04K	﹤0.01%	528
2024 Q3	$21K	Sell	20 -25	-56%	-$27.8K	﹤0.01%	502
2024 Q2	$47.3K	Buy	45 +25	+125%	+$24.2K	﹤0.01%	363
2024 Q1	$17.6K	Hold	20	–	–	﹤0.01%	496
2023 Q4	$17.6K	Hold	20	–	–	﹤0.01%	496
2023 Q3	$16.5K	Hold	20	–	–	﹤0.01%	528
2023 Q2	$14.4K	Hold	20	–	–	﹤0.01%	536
2023 Q1	$16.4K	Hold	20	–	–	﹤0.01%	506
2022 Q4	$14.4K	Buy	+20	New	+$14.8K	﹤0.01%	534

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Armstrong Advisory Group's REGN Position: Q2 2026 in Review

Armstrong Advisory Group held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 6 shares worth $3.74K. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Armstrong Advisory Group first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $47.3K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Armstrong Advisory Group held 6 shares of Regeneron Pharmaceuticals worth $3.74K as of Q2 2026.
Armstrong Advisory Group left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #821 holding.
Armstrong Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
Armstrong Advisory Group's Regeneron Pharmaceuticals position peaked at $47.3K in Q2 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.